Registered title, quoted from ClinicalTrials.gov
Risk-adapted Therapeutic Strategy in +1q NDMM
An open trial on multiple myeloma, registered on ClinicalTrials.gov. Led by First Hospital of Jilin University; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07045168, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Age >=18, or >=65 and fit according to IMWG-FI.
- Newly diagnosed NDMM by 2014 IMWG criteria.
- Adequate organ function for systemic therapy.
- Signed informed consent.
Exclusion Criteria:
- Active infections requiring systemic treatment.
- Unstable angina, NYHA class III-IV heart failure, or uncontrolled arrhythmias.
- History of hematologic or solid tumors treated with chemo/radiotherapy within 5 years.
- Current malignancies requiring therapy.
- Refusal to participate.
Quoted from ClinicalTrials.gov, NCT07045168, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07045168, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.